

What is claimed is:

1. A method of treating a warm-blooded animal having a proliferative disease comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor, in a quantity which is jointly therapeutically effective against a proliferative disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.
2. The method according to claim 1, wherein the proliferative disease is leukemia or Imatinib-resistant leukemia.
3. A method of treating a warm-blooded animal having leukemia, particularly an Imatinib-resistant leukemia, comprising administering to the animal at least one hypusination inhibitor, in a quantity which is therapeutically effective against leukemia and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.
4. A combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
5. Combination according to claim 4 wherein the compound (a) is used in the form of its monomethanesulfonate salt.
6. Combination according to claim 4 or 5, which is a combined preparation or a pharmaceutical composition.
7. A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a proliferative disease of a combination according to claim 4 or 5 and at least one pharmaceutically acceptable carrier.

8. Use of a combination according to any one of claims 4 to 7 for the delay of progression or treatment of a proliferative disease.
9. Use of a combination according to any one of claims 4 to 7 for the preparation of a medicament for the delay of progression or treatment of a proliferative disease.
10. Use of a combination according to any one of claims 8 to 9, wherein the proliferative disease is leukemia or Imatinib-resistant leukemia.
11. Use of at least one hypusination inhibitor for the preparation of a medicament for the delay of progression or treatment of leukemia, particularly Imatinib-resistant leukemia.
12. Use of at least one hypusination inhibitor for the delay of progression or treatment of leukemia, particularly Imatinib-resistant leukemia.
13. A method, a combination, a composition or a use according to any one of claims 1 to 10, in which the combination partners (a) and (b) are administered in synergistically effective amounts.
14. A commercial package comprising a combination according to any one of claims 4 to 7, together with instructions for simultaneous, separate or sequential use thereof in the delay of progression or treatment of a proliferative disease.
15. A method, a combination, a composition, a commercial package or a use according to any one of claims 1 to 14, in wherein the hypusination inhibitor is selected from the group consisting of deferoxamine, ciclopirox, deoxyspergualin, deferiprone and GC-7.
16. A method, a combination, a composition, a commercial package or a use according to any one of claims 1 to 14, in wherein the hypusination inhibitor is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid.
17. A method, a combination, a composition, a commercial package or a use according to any one of claims 1 to 14, in wherein the hypusination inhibitor is ciclopirox.